Mutant KRAS is a well-known oncogenic driver and has remained undruggable for many decades. The development of pan-KRAS inhibitors that target a broad range of mutations is a promising approach to cancer treatment.
Jacobio Pharmaceuticals Co. Ltd. has reported new fused tetracyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.
Jacobio Pharmaceuticals Co. Ltd. has prepared and tested cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers reported to be useful for the treatment of cancer.
Jacobio Pharmaceuticals Co. Ltd. has divulged cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers reported to be useful for the treatment of cancer.
Researchers from Jacobio Pharmaceuticals Co. Ltd. have reported preclinical data for JAB-X1800, an immunostimulatory antibody-drug conjugate (iADC) targeting CD73. JAB-X1800 was developed using an anti-CD73 monoclonal antibody (MAb) for targeted delivery of a highly potent noncyclic dinucleotide STING agonist payload, JAB-27670.
Jacobio Pharmaceuticals Co. Ltd. has synthesized cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers reported to be useful for the treatment of cancer.
Jacobio Pharmaceuticals Co. Ltd. has patented cellular tumor antigen p53 (TP53) (Tyr220Cys mutant) stabilizers reported to be useful for the treatment of cancer.
Jacobio Pharmaceuticals Co. Ltd. has identified new stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer.
